Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BXRXNASDAQ:CMNDNYSE:OGENNASDAQ:RSLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBXRXBaudax Bio$0.02$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,872 shsCMNDClearmind Medicine$0.97-3.5%$1.01$0.85▼$2.30$4.12M0.89877,267 shs24,818 shsOGENOragenics$0.19-2.2%$0.20$0.16▼$2.52$4.08M1.161.67 million shs123,262 shsRSLSReShape Lifesciences$4.76-3.6%$10.33$4.73▼$725.00$3.51M1.48187,017 shs39,283 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBXRXBaudax Bio0.00%0.00%0.00%0.00%0.00%CMNDClearmind Medicine0.00%+3.09%0.00%-22.48%-13.79%OGENOragenics+1.20%-0.15%+3.90%-31.99%-92.26%RSLSReShape Lifesciences-3.52%-17.39%-49.92%-82.36%-98.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBXRXBaudax BioN/AN/AN/AN/AN/AN/AN/AN/ACMNDClearmind Medicine0.1345 of 5 stars0.02.00.00.00.61.70.0OGENOragenicsN/AN/AN/AN/AN/AN/AN/AN/ARSLSReShape Lifesciences0.5782 of 5 stars0.04.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBXRXBaudax Bio 0.00N/AN/AN/ACMNDClearmind Medicine 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/ARSLSReShape Lifesciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBXRXBaudax Bio$1.27M0.90N/AN/A($14.93) per share0.00CMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AOGENOragenics$40K102.01N/AN/A$0.61 per share0.31RSLSReShape Lifesciences$8.01M0.44N/AN/A$29.49 per share0.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBXRXBaudax Bio-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/ACMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%6/12/2025 (Estimated)OGENOragenics-$20.66M-$1.12N/A∞N/AN/A-2,087.95%-486.56%N/ARSLSReShape Lifesciences-$11.39M-$193.23N/A∞N/A-86.36%-179.83%-91.48%N/ALatest BXRX, CMND, RSLS, and OGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025RSLSReShape LifesciencesN/A$18.98N/A$18.98N/A$1.11 million4/4/2025Q4 2024RSLSReShape Lifesciences-$101.50-$47.25+$54.25-$1.89$3.17 million$1.81 million3/13/2025Q1 2025CMNDClearmind MedicineN/A-$0.24N/A-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBXRXBaudax BioN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ARSLSReShape LifesciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBXRXBaudax BioN/A0.070.07CMNDClearmind Medicine0.011.721.72OGENOragenicsN/A1.931.93RSLSReShape LifesciencesN/A1.330.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBXRXBaudax Bio9.05%CMNDClearmind Medicine96.05%OGENOragenics18.71%RSLSReShape Lifesciences22.06%Insider OwnershipCompanyInsider OwnershipBXRXBaudax Bio0.10%CMNDClearmind MedicineN/AOGENOragenics4.90%RSLSReShape Lifesciences0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBXRXBaudax Bio952.46 million52.41 millionNot OptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableOGENOragenics521.48 million10.98 millionN/ARSLSReShape Lifesciences50738,000729,000Not OptionableBXRX, CMND, RSLS, and OGEN HeadlinesRecent News About These CompaniesReShape Lifesciences Inc. Reports First Quarter 2025 Financial Results and Strategic UpdatesMay 21 at 9:40 AM | quiverquant.comReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate UpdateMay 21 at 8:31 AM | globenewswire.comReShape Lifesciences (NASDAQ:RSLS) Stock Passes Above Two Hundred Day Moving Average - Here's WhyMay 12, 2025 | marketbeat.comReShape Lifesciences Inc: ReShape Lifesciences Announces 1-for-25 Reverse Stock SplitMay 7, 2025 | finanznachrichten.deReShape Lifesciences Announces 1-for-25 Reverse Stock SplitMay 7, 2025 | globenewswire.comStocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock ChatterMay 5, 2025 | msn.comPRISM Mid-Day Movers: Weight Loss Index Gains on Positive Data, Biotech Slumps on Disappointing ResultsMay 3, 2025 | theglobeandmail.comReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation SymposiumMay 2, 2025 | globenewswire.comReShape Lifesciences amends asset purchase terms with NinjourApril 30, 2025 | investing.comReShape Lifesciences Inc: ReShape Lifesciences Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon SystemApril 28, 2025 | finanznachrichten.deReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon SystemApril 28, 2025 | globenewswire.comReShape Lifesciences® Secures Patent for Innovative Vagal Neuromodulation Device to Treat Type 2 Diabetes with Enhanced Energy EfficiencyApril 23, 2025 | nasdaq.comReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation SystemApril 22, 2025 | msn.comReShape Lifesciences skyrockets after receiving U.S. patent for diabetes neuromodulation technologyApril 21, 2025 | msn.comReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation TechnologyApril 21, 2025 | globenewswire.comReShape Lifesciences enters agreement with HaifaApril 10, 2025 | markets.businessinsider.comReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)April 10, 2025 | seekingalpha.comReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. MarketApril 9, 2025 | globenewswire.comReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate UpdateApril 7, 2025 | globenewswire.comReShape Lifesciences Delays Yearly Report FilingApril 1, 2025 | tipranks.comRESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLSMarch 21, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBXRX, CMND, RSLS, and OGEN Company DescriptionsBaudax Bio NASDAQ:BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Clearmind Medicine NASDAQ:CMND$0.96 -0.04 (-3.50%) Closing price 03:52 PM EasternExtended Trading$0.96 -0.01 (-0.83%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Oragenics NYSE:OGEN$0.19 0.00 (-2.21%) Closing price 04:00 PM EasternExtended Trading$0.19 0.00 (-1.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.ReShape Lifesciences NASDAQ:RSLS$4.76 -0.18 (-3.64%) Closing price 04:00 PM EasternExtended Trading$4.77 +0.01 (+0.21%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
